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Abstract 
 
Typhoid fever is a disease affect many people in developing countries including 
Indonesia. Prevention can be aided by vaccination to the bacteria; however it still needs 
further research. This research is aimed to determine the immunogenicity of fim-C native 
protein Salmonella typhi in vivo as a vaccine candidate in ddY mice. Experimental 
method is used in this research. This research used antigen of pure fim-C native 
recombinant protein from its previous research. The ddY mice are categorized into five 
groups, namely experiment group 1 (protein Fim-C+Freund's Complete/Incomplete 
Adjuvant), experiment group 2 (protein Fim-C S. typhi), control group 1 (FCA/FIA 
adjuvants), control group 2 (PBS1x), and normal group (PBS1x). The results showed that 
the ddY mice produced antibody response after subcutaneous injection of the Fim-C S. 
typhi native protein +adjuvant or without adjuvant. The antibody responses with Fim-C S. 
typhi native protein as antigen+adjuvant gave higher absorbans than the Fim-C antigen 
without adjuvant. It is also showed that the antibody titer from the first to fourth injection 
has gradually increased. These data showed that Fim-C S. Typhi native protein had higher 
immunogenicity. It is concluded that the Fim-C S. typhi native protein can be used as a 
potential recombinant vaccine candidate against typhoid fever. 
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INTRODUCTION 
 
Typhoid fever is one of diseases suffered by most people in developing countries, including 
Indonesia. Typhoid fever is suffered ranging from children to adults. Typhoid fever is easily 
transmitted to human through food and drink contaminated by Salmonella typhi bacteria in the 
poor standards of environment hygiene. Typhoid fever happens in Indonesia with an average of 
900,000 cases per year. The mortality rate is more than 20,000 cases or 91% of all cases ranging 
in the age of 3-19 years old. The mortality rate increases in every year [Crump and Mintz, 2010; 
Verry, 2011]. Thus serious action to prevent and overcome typhoid fever in Indonesia is highly 
needed. 
 
Salmonella typhi bacteria has Fim-C protein, called  fimbriae. Fim-C protein, a kind of protein 
on the surface of bacteria cell, acts as important mediators used for interaction or adharence 
against host cell [Burrows, 2005; Muktiningsih et al, 2009]. Proteins on the surface of bacteria 
cell as Fim-C can be used as an antigen; it also induces immune response well [Verma et al.,  
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2009; Toobak et al., 2013; Yang et al., 2013; Moreno et al., 2013]. It is presumed that Fim-C 
proteins on Salmonella typhi can be potentially used as recombinant vaccine for typhoid fever 
prevention. Due to its higher level of safety, recombinant vaccine is chosen to be further 
developed rather than conventional non recombinant vaccine that uses attenuated virus. 
 
In the prior research, researchers team from UNJ has succeeded in Fim-C Salmonella typhi gene 
cloning and sub-cloning on the cloning and expression vectors and its protein purification in 
both native form and inclusion bodies [Anggraeni R et al, 2012; Pratiwi E et al. 2013; 
Muktiningsih et al, 2013].  This research is aimed to determine the activity of Fim-C S. typhi 
recombinant protein in its native form as an antigen in mice ddY through immune response 
analysis. This information is very important in the development of the potential recombinant 
Fim-C S. typhi protein as candidate for recombinant vaccine to prevent typhoid fever in human. 
 
RESEARCH METHOD 
 
A. Production of anti Fim-C S. typhi antibodies 
 
Production of anti Fim-C Salmonella typhi native antibodies consisted of preparation stage for 
mice ddY as animal test, preparation stage for Fim-C S. typhi Native recombinant protein as 
antigene, immunization and antibodies production, and mice serum/anti-FimC S. typhi 
antibodies isolation [Harlow and Lane, 1988; Deutsher, 1990; Noer, et al., 1992; Jennings, 
1995].  
 
A.1. Preparation stage for mice ddY as animal test 
 
Production of anti Fim-C antibodies was conducted in LABTIAP (Agricultural Industry 
Technology Development and Biomedical Laboratory) BPPT-Serpong. The production of anti-
Fim C S. typhi Native antibodies performed on 40 male mice ddY strains, age of 5-6 weeks and 
weigh of 17-24 grams.  Mice were obtained from PT Biofarma Bandung. Mice were maintained 
in cages placed in the treatment room with temperature condition of 20-240C and 20-70% 
humidity. Treatment room was made sound-proof and impermeable to keep the air pressure 
lower than the surrounding so the odor will not come out. Every testing was conducted in 
different room. 4-8 mice are placed in individual cages of polycarbonate (with stainless steel 
cover) with size of 41,5x27x15 cm3 each. The individual cages were arranged in 3 level 
stainless steel racks. During the conditioning process, mice were weighed on day 0, day 3 and 
day 5. Cage, food, health, and activity checks were also done regularly. The conditioning 
process is as long as a week. 
 
Mice were grouped into three major groups, namely the experiment group (KP), the sick control 
group (KS) and the normal control group (KN). Experimental group had two sub groups; group 
immunized by mixture of Fim-C native protein and Frued complete/Incomplete adjuvant 
(FCA/FIA) which consists of 8 mice (KP-1) and group immunized by Fim-C native protein 
which consists of 8 mice (KP2). The sick control had two sub groups; group immunized by 
FCA/FIA which consists of 8 mice  (KS-1) and group immunized by Phosphate Buffer Saline 
(PBS 1x) which consists of 8 mice (KS-2).  The normal control group  (KN) immunized by 
Phosphate Buffer Saline (PBS 1x) consists of 4 mice.  In the challenge test, only experiment 
group (KP) and sick control group (KS) were infected by S. typhi bacteria. The normal control 
group (KN) was not be infected by S. typhi bacteria. After the conditioning process, the 
researcher took blood from mice’s eyes as much as 1-2 mL as pre immune serum. A day prior to 
collect pre-immune serum, mice were conditioned to food-fasting. 
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A.2. Preparation stage for Fim-C S. typhi Native recombinant protein as antigene 
 
As many as 25-100 µg Fim-C S. typhi native protein from previous results was disolved witth 
PBS 1x bufer in  Eppendorf 1,5 mL tube to have a total volume of 100-250 µL. Freund’s 
complete adjuvant (FCA) or Freund’s incomplete adjuvant (FIA) were added with ratio 1:1. 
Then performed homogenized mix using vortexs until the mix turned white [Harlow and Lane, 
1988; Jenings, 1995]. 
A.3. Immunization and Antibodies Production 
 
Immunization was carried out on the backs of mice in the front section near head 
subcutaneously as much as 2-3 points for one-time injection. On the first immunization 20 µg 
Fim C S. typhi native protein that has been prepared as an antigen was mixed with Freund’s 
complete Adjuvant. One week after the first injection researchers took blood sample from mice’s 
eyes to prepare the serum. One week after the first injection researchers conducted boosting 
with 40 g Fim-C mixed with Freund’s incomplete Adjuvant. The second and third boosting were 
conducted with the 80 g Fim-C after one week of the second and the third  injections to obtain 
the optimal antibody amount [Harlow and Lane, 1988; Noer, 1992]. 
A.4. Mice serum/anti-FimC S. typhi antibodies isolation 
 
Blood sample from mice’s eyes was collected on tubes of centrifuges sterile. Blood sample was 
incubated at temperature of 370C for 30-60 minutes to a visible separation between serum and 
platelets. Centrifugation was carried out for 10 minutes with the speed of 5000 g at a 4 oC. Clear 
liquid/serum was taken out and kept in Eppendorf. Then the serum was stored in –200C [Harlow 
and Lane, 1988]. 
 
B. Characterization of anti Fim-C S. typhi  Native antibodies by ELISA 
 
Antibodies used in the formation analysis of anti-FimC S. typhi antibodies was mice serum from 
Bleed I-Bleed IV. Formation analysis of anti-Fim-C protein S. typhi antibodies from day 0 (pre-
immune serum) until the 6 weeks was obtained by Enzyme Link Immunosorbant Assay (ELISA).  
 
Antigen (30–300 ng Fim-C S. typhi native protein in50 µL fosfat bufer, 1x PBS) was incubated 
in microtiter plate wells (IWAKI) in room temperature overnight. Every well was washed 3 
times each with 1x PBS  containing 1 mM MgCl2 and 0,05% (v/v) Tween-20 (wash buffer). 
After they were washed, researchers added into 150 µL 5% blotto (5 g skim milk in 100 mL 1x 
PBS) in every well. And then the microtiter plate was incubated at 370C for 1 hour. After the 
incubation wells were washed as much as 3 times with wash buffer. As many as 50 µL mice 
serum (from bleed I/pre-immune serum) - bleed V (fifth weeks), by  100x and 300x dilution 
were added into each well with prepared ELISA design,and then put them into incubation at  
370C for one hour. The microtiter plate wells were washed with wash buffer 3 times. After 
washing process, 50 µL secondary antibodies was added into each well (anti IgG-mice-HRP 
dilution 1: 5000 with  1x PBS) [Thermo Scientific Biogen, 2013], and incubated in 370C for 1 
hour. After the incubation, the microtiter plate wells were washed with wash buffer 3 times. As 
much as100 µL substrate TMB (3,3’,5,5’-Tetramethylbenzidine) solution was added into each 
well and incubated at 370C for 30 minutes (produced blue color). After the  incubation, the 
reaction was stopped by adding 50 µL H2SO4 2M (produced yellow color). Next, the absorbance 
reading was conducted using ELISA-Reader (Microplate Reader) at wavelength 450 nm [Noer, 
1992; Deutsher, 1990; Muktiningsih, 2005; Thermo Scientific, Biogen, 2013]. After the 
formation of antibodies were known to the maximum researchers collected serum in large 
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amount or bleeding terminal as much as 5-10 mL of blood. 
 
RESULT AND DISCUSSION 
 
A.Production of  anti-Fim-C S. typhi native Antibodies 
 
The results of animal conditioning process and pre-immune serum collection process 
 
Health, weight, diet, and physical condition checks and observation during the conditioning 
process showed good result. This was demonstrated by the increase in weight on average  3-5 
gram/mice. The observed physical condition of feathers and motion also showed patterns of 
activity that corresponds to standard conditions. The conditioning place and picture of test 
animals are presented in figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  The conditioning place and picture of test animals. Mice are grouped into 5 cages. 
Every cages containing 8 mice for the experimental groups (KP) and the sick 
control group (KS) and containing 4 mice for normal group (KN).  
 
The retrieval results of pre-immune serum from sinus orbitalis eyes produced 0,5-1 mL 
blood/mice and it was 0,2-0,5 mL serum of the total blood samples. Serums were stored in 
frezer with temperture -20oC for further purposes. The pupose of taking pre-immune serum is as 
a negative control to the formation of anti Fim-C antibodies. This is aimed to ensure that there is 
no interaction occurs between Fim-C protein as antigene with mice antibodies before 
imunization.  
 
The production results of anti-FimC S. typhi antibodies 
 
Production of anti-FimC S. typhi native antibodies in experimental and control groups was 
performed in 6 weeks. The process consisted of  the first imunization with 20 µg Fim C S. typhi 
native protein, boosting-1 with 40 µg Fim-C S. typhi native protein. Boosting-2 and boosting-3 
were conducted by using 80 µg Fim-C S. typhi native protein. Each step gave a total amount 
serum 0,2-0,5 mL. After ELISA data was obtained with highest absorbance values, in the sixth 
week researchers collected blood samples of 4 mice from experimental groups  by the 
maximum as much as 5-10 mL. The blood was prepared to serum containing anti-Fim C S. typhi 
antibodies as many as 2-4 mL/mice. 
 
B. Characterization of  anti Fim-C S. typhi native antibodies by ELISA 
 
The formation analysis of antibodies used as a primer was taken from mice serum of Bleed I-
Bleed IV. ELISA analysis was performed on 4 mice from each group,that are: experimental 
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group I (immunized by Fim-C S. typhi native Protein mixed with Freud complete/incomplete 
adjuvant-KP-1), experimental group 2 (immunized by Fim-C S. typhi native Protein without 
adjuvant-KP2), control group-1 (immunized by Freud complete/ incomplete adjuvant, KS1), 
control group-2 (immunized by 1x PBS buffer, KS-2), and normal group (immunized by 1x 
PBS buffer, KN). The result of development of antibodies formation from 4 mice ddY from 
each group are presented in table 1. While the analysis results of development formation of anti-
Fim C S. typhi antibodies is presented in figure 2 and figure 3.   
 
Table 1.  The data values of  absorbance on development anti Fim-C S. typhi native antibodies 
at experimental group (KP) and  the sick control group (KS) at antigene concentration 
100 ng and 300 ng 
 
bleed to- 
Experimental 
Group- 1 (KP1) 
Experimental  
Group- 2 (KP2) 
The Sick Control 
Group-1 (KS1) 
The Sick Control 
Group-2 (KS2) 
100 ng 300 ng 100 ng 300 ng 100 ng 300 ng 100 ng 300 ng 
bleed -0 0,0285 0,04 0,01125 0,00975 0,048333 0,009333 0,01 0,01 
bleed -1 0,0055 0,01825 0,00275 0,008 0,027333 0,009667 0,0165 0,0165 
bleed -2 0,19675 0,23275 0,04125 0,09575 0,029 0,037 0,0365 0,0365 
bleed -3 0,2715 0,44175 0,19 0,2225 0,042667 0,037667 0,0335 0,0335 
bleed -4 0,27925 0,5175 0,1805 0,20275 0,04 0,043 0,047 0,047 
        
 
Based on the results of analysis on the development of formation anti-Fim C S. typhi antibodies 
by ELISA shown in Table 1 that Fim-C S. typhi native protein with or whithout adjuvants give 
satisfied immune response. This is shown by an increase absorbance values from  Bleed 0-Bleed 
4. The increase of color intensity or absorbance values showed increase in the amount of 
antibody titer that interacted with  Fim-C S.typhi antigene. The blue color was from the 
oxidation TMB substrate (3,3’,5,5’-Tetramethylbenzidine) to 3,3',5,5'-tetramethylbenzidine 
diimine by  Horse Redish Peroksidase enzyme which  bounded to secondary antibodies.  Color 
formation reaction was stopped by adding 50 µL H2SO4 and resulted yellow color and measured 
at wavelenghts 450 nm [Thermo scientific Biogen, 2013] 
 
Data presented in table 1 or figure 2 and figure 3 give information that induction by protein 
Fim-C S. typhi Native +Adjuvant FCA/FIA as antigene produced higher antibodies than by 
protein Fim-C S. typhi Native+ PBS 1x. This is in accordance with the literature review stated 
that the Frued complete/incomplete adjuvant (FCA/FIA) can enhance the formation of immune 
response [Harlow and Lane, 1988; Fiorino et al, 2012; Moreno et al., 2013]. These results also 
provide information on specific characters of Fim-C S. typhi native protein that if recombinant 
protein mixed with adjuvants the resulting immune response will be higher than without 
adjuvants.  The information is also essential that Fim-C S. typhi native protein without adjuvant 
can also provide a good immune response.  
 
This information is very important as the scientific foundation to conclude that the withdrawal 
of recombinant protein molecule of Fim-C S. typhi native is candidate vaccine recombinant. The 
results of literature analysis stated that the recombinant vaccine has many advantages. It (1) has 
higher safety for patients  (2) has higher purity (3) generates more spesific immune response (4) 
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can be produce in large quantities (5) is easy in production and storage, and some of other 
advantages [Harlow and Lane, 1988; Fiorino et al, 2012]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Graphic analysis of the formation of anti Fim-C S. typhi native antibodies in 
the experimental and the control group. (A) graphic of formation of antibodies 
in experimental group-1 (KP-1). (B) graphic of formation of antibodies in 
experimental group-2 (KP2), (C) graphic of control group-1 (KS1), (D) graphic of 
control group-2 (KS2). The x-axis showed the development of immunization from 
each bleed 0-4. The y-axis shows the value of absorbance reading of ELISA 
reader.  Blue and red colored diagram shows the amount of  protein FimC S. typhi 
recombinant 100 ng dan 300 ng as antigenes. 
 
 
 
 
 
 
 
 
 
 
 
 
  Proceeding of  International Conference On Research, Implementation And Education  
Of Mathematics And Sciences 2014, Yogyakarta State University, 18-20 May 2014   
       
 
 
C-117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  The graphic result of immunogenicity test on  antigens Fim-C S. typhi Native 
protein.  The blue line shows the value of absorbance for a group of mice 
immunized by Fim-C S. typhi native+Adjuvant FCA/FIA as antigens. The red line 
shows the value of absorbance for a group of mice immunized by Fim-C S. typhi 
native+1x PBS as antigens. The green line shows the value of absorbance for a 
group of mice immunized by Adjuvant FCA/FIA+1x PBS as antigens.  The green 
line shows the value of absorbance for a group of mice immunized by Adjuvant 
FCA/FIA+1x PBS as antigens. The violet  line shows the value of absorbance for a 
group of mice immunized by 1x PBS as antigens. Condition of ELISA performed 
on serum dilutiom 100x and secondary antibodies  dilution 5000x. 
 
CONCLUSION AND SUGGESTION 
 
Fim-C S, typhi Protein in native form has ben succesfully used as an antigen specific in 
production of anti Fim-C S. typhi antibodies in vivo in mice ddY. The generated formation of 
immune response is indicated by the color change of substrate after interaction between Fim-C 
S. typhi antigen with anti Fim-C S. typhi antibodies. From Bleed 1-Bleed IV, the establishment 
of spesific anti Fim-C S. typhi antibodies with Fim-C + adjuvant FCA/FIA as antigene gives 
higher immune response than without  adjuvants. The result also provides information that Fim-
C S. typhi Typhi protein has good nature of imunogenicity because it is able to make higher 
response immune without the addition of adjuvant and adjuvant  FCA/FIA. So that it can be 
inferred that Fim-C S. typhi native Protein can be used as vaccine candidates. 
 
Significant supporting data about vaccine’s standardized test and clinical trials for human are 
still needed to make recombinant protein molecules of Fim-C S. typhi native serve as a safe and 
inexpensive molecular vaccine.  The information generated in this study could be made of the 
scientific basis for the further development of recombinant vaccines for typhoid fever in 
humans, especially in Indonesia. 
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